News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK's National Institute for Clinical Excellence (NICE) Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics NV (TBGNF)' JETREA® for Treatment of Vitreomacular Traction and Macular Hole



9/3/2013 8:06:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEUVEN, Belgium, September 2, 2013 /PRNewswire/ --

Metamorphopsia confirmed as a severe and distressing symptom deserving immediate attention and early treatment with reimbursement

• NICE FAD recommending reimbursement of JETREA for treatment of VMT patients, from early stage to late-stage (full thickness macular hole (FTMH) < 400 microns), when severe and distressing symptoms; patients with ERMs are excluded.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES